U
U.S. Stem Cell, Inc.
USRM
$0.0001
$0.000.00%
E
Sell
12/28/2023Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to E+ from D- on 12/28/2023 due to a decline in the volatility index.
U.S. Stem Cell, Inc. (USRM) was downgraded to E+ from D- on 12/28/2023 due to a decline in the volatility index.
D
Sell
12/13/2023Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to D- from E+ on 12/13/2023 due to an increase in the volatility index and total return index.
U.S. Stem Cell, Inc. (USRM) was upgraded to D- from E+ on 12/13/2023 due to an increase in the volatility index and total return index.
E
Sell
11/28/2023Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to E+ from D- on 11/28/2023 due to a decline in the volatility index.
U.S. Stem Cell, Inc. (USRM) was downgraded to E+ from D- on 11/28/2023 due to a decline in the volatility index.
D
Sell
11/13/2023Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to D- from E+ on 11/13/2023 due to an increase in the volatility index.
U.S. Stem Cell, Inc. (USRM) was upgraded to D- from E+ on 11/13/2023 due to an increase in the volatility index.
E
Sell
5/22/2023Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to E+ from D- on 5/22/2023 due to a decline in the volatility index.
U.S. Stem Cell, Inc. (USRM) was downgraded to E+ from D- on 5/22/2023 due to a decline in the volatility index.
D
Sell
3/29/2023Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to D- from E+ on 3/29/2023 due to an increase in the volatility index and total return index.
U.S. Stem Cell, Inc. (USRM) was upgraded to D- from E+ on 3/29/2023 due to an increase in the volatility index and total return index.
E
Sell
3/14/2023Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index.
U.S. Stem Cell, Inc. (USRM) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/9/2023Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
U.S. Stem Cell, Inc. (USRM) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to E+ from D on 2/8/2023 due to a noticeable decline in the total return index and volatility index.
U.S. Stem Cell, Inc. (USRM) was downgraded to E+ from D on 2/8/2023 due to a noticeable decline in the total return index and volatility index.
D
Sell
5/5/2022Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index.
U.S. Stem Cell, Inc. (USRM) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index.
D
Sell
4/20/2022Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D- from D on 4/20/2022 due to a decline in the growth index and total return index. Total revenue declined 58.81% from $57.3 to $23.6, and operating cash flow declined 5.19% from -$206 to -$216.7.
U.S. Stem Cell, Inc. (USRM) was downgraded to D- from D on 4/20/2022 due to a decline in the growth index and total return index. Total revenue declined 58.81% from $57.3 to $23.6, and operating cash flow declined 5.19% from -$206 to -$216.7.
D
Sell
11/10/2021Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to D from E+ on 11/10/2021 due to a major increase in the growth index. Total revenue increased 61.86% from $35.4 to $57.3, EBIT increased 35.38% from -$781.2 to -$504.8, and operating cash flow increased 35.16% from -$317.7 to -$206.
U.S. Stem Cell, Inc. (USRM) was upgraded to D from E+ on 11/10/2021 due to a major increase in the growth index. Total revenue increased 61.86% from $35.4 to $57.3, EBIT increased 35.38% from -$781.2 to -$504.8, and operating cash flow increased 35.16% from -$317.7 to -$206.
E
Sell
11/8/2021Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to E+ from D- on 11/08/2021.
U.S. Stem Cell, Inc. (USRM) was downgraded to E+ from D- on 11/08/2021.
D
Sell
11/3/2021Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D- from D on 11/3/2021 due to a decline in the volatility index.
U.S. Stem Cell, Inc. (USRM) was downgraded to D- from D on 11/3/2021 due to a decline in the volatility index.
D
Sell
10/14/2021Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to D from D- on 10/14/2021 due to an increase in the volatility index.
U.S. Stem Cell, Inc. (USRM) was upgraded to D from D- on 10/14/2021 due to an increase in the volatility index.
D
Sell
9/28/2021Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D- from D on 9/28/2021 due to a decline in the volatility index.
U.S. Stem Cell, Inc. (USRM) was downgraded to D- from D on 9/28/2021 due to a decline in the volatility index.
D
Sell
9/9/2021Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to D from D- on 9/9/2021 due to an increase in the volatility index.
U.S. Stem Cell, Inc. (USRM) was upgraded to D from D- on 9/9/2021 due to an increase in the volatility index.
D
Sell
8/23/2021Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D- from D on 8/23/2021 due to a noticeable decline in the total return index, volatility index and growth index. EBIT declined 60.34% from -$487.2 to -$781.2, total revenue declined 58.06% from $84.4 to $35.4, and operating cash flow declined 0.06% from -$317.5 to -$317.7.
U.S. Stem Cell, Inc. (USRM) was downgraded to D- from D on 8/23/2021 due to a noticeable decline in the total return index, volatility index and growth index. EBIT declined 60.34% from -$487.2 to -$781.2, total revenue declined 58.06% from $84.4 to $35.4, and operating cash flow declined 0.06% from -$317.5 to -$317.7.
D
Sell
7/16/2021Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to D from D- on 7/16/2021 due to a large increase in the total return index, volatility index and growth index.
U.S. Stem Cell, Inc. (USRM) was upgraded to D from D- on 7/16/2021 due to a large increase in the total return index, volatility index and growth index.
D
Sell
12/30/2020Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D- from D on 12/30/2020 due to a decline in the total return index and volatility index.
U.S. Stem Cell, Inc. (USRM) was downgraded to D- from D on 12/30/2020 due to a decline in the total return index and volatility index.
D
Sell
12/15/2020Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to D from D- on 12/15/2020 due to an increase in the total return index and volatility index.
U.S. Stem Cell, Inc. (USRM) was upgraded to D from D- on 12/15/2020 due to an increase in the total return index and volatility index.
D
Sell
8/3/2020Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D- from D on 8/3/2020 due to a decline in the total return index and volatility index.
U.S. Stem Cell, Inc. (USRM) was downgraded to D- from D on 8/3/2020 due to a decline in the total return index and volatility index.
D
Sell
7/17/2020Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to D from D- on 7/17/2020 due to an increase in the total return index and growth index.
U.S. Stem Cell, Inc. (USRM) was upgraded to D from D- on 7/17/2020 due to an increase in the total return index and growth index.
D
Sell
5/1/2020Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index, solvency index and valuation index.
U.S. Stem Cell, Inc. (USRM) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index, solvency index and valuation index.
D
Sell
11/12/2019Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D from D+ on 11/12/2019 due to a major decline in the growth index, total return index and solvency index. EBIT declined 4,585.34% from -$34.1 to -$1.6M, operating cash flow declined 133.01% from -$195.4 to -$455.3, and earnings per share declined from -$0.0021 to -$0.0041.
U.S. Stem Cell, Inc. (USRM) was downgraded to D from D+ on 11/12/2019 due to a major decline in the growth index, total return index and solvency index. EBIT declined 4,585.34% from -$34.1 to -$1.6M, operating cash flow declined 133.01% from -$195.4 to -$455.3, and earnings per share declined from -$0.0021 to -$0.0041.
D
Sell
10/21/2019Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to D+ from D on 10/21/2019 due to an increase in the total return index and volatility index.
U.S. Stem Cell, Inc. (USRM) was upgraded to D+ from D on 10/21/2019 due to an increase in the total return index and volatility index.
D
Sell
9/11/2019Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D from D+ on 9/11/2019 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.0018 to -$0.0021, and total revenue declined 0.83% from $1.31M to $1.3M.
U.S. Stem Cell, Inc. (USRM) was downgraded to D from D+ on 9/11/2019 due to a major decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.0018 to -$0.0021, and total revenue declined 0.83% from $1.31M to $1.3M.
D
Sell
4/4/2019Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D+ from C- on 4/4/2019 due to a noticeable decline in the total return index and growth index. Earnings per share declined from -$0.0009 to -$0.0012.
U.S. Stem Cell, Inc. (USRM) was downgraded to D+ from C- on 4/4/2019 due to a noticeable decline in the total return index and growth index. Earnings per share declined from -$0.0009 to -$0.0012.
C
Hold
3/4/2019Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to C- from D+ on 3/4/2019 due to a noticeable increase in the total return index and volatility index.
U.S. Stem Cell, Inc. (USRM) was upgraded to C- from D+ on 3/4/2019 due to a noticeable increase in the total return index and volatility index.
D
Sell
12/21/2018Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D+ from C- on 12/21/2018 due to a major decline in the total return index and volatility index.
U.S. Stem Cell, Inc. (USRM) was downgraded to D+ from C- on 12/21/2018 due to a major decline in the total return index and volatility index.
C
Hold
12/13/2018Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to C- from C on 12/13/2018 due to a decline in the volatility index.
U.S. Stem Cell, Inc. (USRM) was downgraded to C- from C on 12/13/2018 due to a decline in the volatility index.
C
Hold
11/28/2018Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to C from C- on 11/28/2018 due to an increase in the volatility index and valuation index.
U.S. Stem Cell, Inc. (USRM) was upgraded to C from C- on 11/28/2018 due to an increase in the volatility index and valuation index.
C
Hold
11/8/2018Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to C- from D+ on 11/8/2018 due to a major increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.0034 to -$0.0009, EBIT increased 73.42% from -$823.3 to -$218.8, and the quick ratio increased from 0.24 to 0.24.
U.S. Stem Cell, Inc. (USRM) was upgraded to C- from D+ on 11/8/2018 due to a major increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.0034 to -$0.0009, EBIT increased 73.42% from -$823.3 to -$218.8, and the quick ratio increased from 0.24 to 0.24.
D
Sell
10/24/2018Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D+ from C- on 10/24/2018 due to a decline in the volatility index.
U.S. Stem Cell, Inc. (USRM) was downgraded to D+ from C- on 10/24/2018 due to a decline in the volatility index.
C
Hold
10/3/2018Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to C- from D+ on 10/3/2018 due to an increase in the total return index and volatility index.
U.S. Stem Cell, Inc. (USRM) was upgraded to C- from D+ on 10/3/2018 due to an increase in the total return index and volatility index.
D
Sell
9/17/2018Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D+ from C- on 9/17/2018 due to a decline in the total return index and volatility index.
U.S. Stem Cell, Inc. (USRM) was downgraded to D+ from C- on 9/17/2018 due to a decline in the total return index and volatility index.
C
Hold
8/31/2018Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to C- from D+ on 8/31/2018 due to an increase in the total return index.
U.S. Stem Cell, Inc. (USRM) was upgraded to C- from D+ on 8/31/2018 due to an increase in the total return index.
D
Sell
8/14/2018Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D+ from C- on 8/14/2018 due to a large decline in the growth index and total return index. EBIT declined 8,752.69% from -$9.3 to -$823.3, earnings per share declined from -$0.0004 to -$0.0034, and operating cash flow declined 102.96% from $688.7 to -$20.4.
U.S. Stem Cell, Inc. (USRM) was downgraded to D+ from C- on 8/14/2018 due to a large decline in the growth index and total return index. EBIT declined 8,752.69% from -$9.3 to -$823.3, earnings per share declined from -$0.0004 to -$0.0034, and operating cash flow declined 102.96% from $688.7 to -$20.4.
C
Hold
7/20/2018Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to C- from D+ on 7/20/2018 due to an increase in the total return index and valuation index.
U.S. Stem Cell, Inc. (USRM) was upgraded to C- from D+ on 7/20/2018 due to an increase in the total return index and valuation index.
D
Sell
5/18/2018Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D+ from C- on 5/18/2018 due to a large decline in the growth index, total return index and valuation index. Earnings per share declined from $0.001 to -$0.0004, and EBIT declined 106.12% from $152 to -$9.3.
U.S. Stem Cell, Inc. (USRM) was downgraded to D+ from C- on 5/18/2018 due to a large decline in the growth index, total return index and valuation index. Earnings per share declined from $0.001 to -$0.0004, and EBIT declined 106.12% from $152 to -$9.3.
C
Hold
5/10/2018Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to C- from C on 5/10/2018 due to a decline in the total return index.
U.S. Stem Cell, Inc. (USRM) was downgraded to C- from C on 5/10/2018 due to a decline in the total return index.
C
Hold
4/17/2018Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to C from C- on 4/17/2018 due to a major increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.0028 to $0.001, EBIT increased 114.38% from -$1.06M to $152, and debt to equity declined from -0.69 to -0.73.
U.S. Stem Cell, Inc. (USRM) was upgraded to C from C- on 4/17/2018 due to a major increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.0028 to $0.001, EBIT increased 114.38% from -$1.06M to $152, and debt to equity declined from -0.69 to -0.73.
C
Hold
2/28/2018Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to C- from D+ on 2/28/2018 due to an increase in the volatility index and total return index.
U.S. Stem Cell, Inc. (USRM) was upgraded to C- from D+ on 2/28/2018 due to an increase in the volatility index and total return index.
D
Sell
12/20/2017Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D+ from C- on 12/20/2017 due to a major decline in the growth index, total return index and volatility index. EBIT declined 842.8% from $142.3 to -$1.06M, earnings per share declined from -$0.0013 to -$0.0028, and operating cash flow declined 53.54% from $517.4 to $240.4.
U.S. Stem Cell, Inc. (USRM) was downgraded to D+ from C- on 12/20/2017 due to a major decline in the growth index, total return index and volatility index. EBIT declined 842.8% from $142.3 to -$1.06M, earnings per share declined from -$0.0013 to -$0.0028, and operating cash flow declined 53.54% from $517.4 to $240.4.
C
Hold
10/27/2017Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to C- from C on 10/27/2017 due to a decline in the volatility index.
U.S. Stem Cell, Inc. (USRM) was downgraded to C- from C on 10/27/2017 due to a decline in the volatility index.
C
Hold
10/10/2017Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to C from C- on 10/10/2017 due to an increase in the volatility index.
U.S. Stem Cell, Inc. (USRM) was upgraded to C from C- on 10/10/2017 due to an increase in the volatility index.
C
Hold
9/25/2017Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to C- from C on 9/25/2017 due to a decline in the total return index and volatility index.
U.S. Stem Cell, Inc. (USRM) was downgraded to C- from C on 9/25/2017 due to a decline in the total return index and volatility index.
C
Hold
8/9/2017Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to C from C- on 8/9/2017 due to a major increase in the total return index, growth index and solvency index. EBIT increased 439.62% from -$41.9 to $142.3, operating cash flow increased 92.84% from $268.3 to $517.4, and earnings per share increased from -$0.0112 to -$0.0013.
U.S. Stem Cell, Inc. (USRM) was upgraded to C from C- on 8/9/2017 due to a major increase in the total return index, growth index and solvency index. EBIT increased 439.62% from -$41.9 to $142.3, operating cash flow increased 92.84% from $268.3 to $517.4, and earnings per share increased from -$0.0112 to -$0.0013.
C
Hold
6/2/2017Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to C- from D+ on 6/2/2017 due to an increase in the total return index, efficiency index and solvency index. The quick ratio increased from 0.05 to 0.1, total capital increased 20.45% from -$2.83M to -$2.25M, and debt to equity declined from -0.65 to -0.7.
U.S. Stem Cell, Inc. (USRM) was upgraded to C- from D+ on 6/2/2017 due to an increase in the total return index, efficiency index and solvency index. The quick ratio increased from 0.05 to 0.1, total capital increased 20.45% from -$2.83M to -$2.25M, and debt to equity declined from -0.65 to -0.7.
D
Sell
3/31/2017Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to D+ from D on 3/31/2017 due to an increase in the volatility index, growth index and total return index.
U.S. Stem Cell, Inc. (USRM) was upgraded to D+ from D on 3/31/2017 due to an increase in the volatility index, growth index and total return index.
D
Sell
3/16/2017Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D from D+ on 3/16/2017 due to a decline in the volatility index and efficiency index.
U.S. Stem Cell, Inc. (USRM) was downgraded to D from D+ on 3/16/2017 due to a decline in the volatility index and efficiency index.
D
Sell
3/2/2017Upgraded
U.S. Stem Cell, Inc. (USRM) was upgraded to D+ from D on 3/2/2017 due to an increase in the volatility index, growth index and total return index. Operating cash flow increased 150.43% from -$103.5 to $52.2, and total revenue increased 7.61% from $678.2 to $729.8.
U.S. Stem Cell, Inc. (USRM) was upgraded to D+ from D on 3/2/2017 due to an increase in the volatility index, growth index and total return index. Operating cash flow increased 150.43% from -$103.5 to $52.2, and total revenue increased 7.61% from $678.2 to $729.8.
D
Sell
3/11/2016Downgrade
U.S. Stem Cell, Inc. (USRM) was downgraded to D from C on 3/11/2016 due to a substantial decline in the volatility index, valuation index and total return index.
U.S. Stem Cell, Inc. (USRM) was downgraded to D from C on 3/11/2016 due to a substantial decline in the volatility index, valuation index and total return index.
C
Hold
9/8/2015Downgrade
Bioheart, Inc. (BHRT) was downgraded to C from C+ on 9/8/2015 due to a noticeable decline in the volatility index.
Bioheart, Inc. (BHRT) was downgraded to C from C+ on 9/8/2015 due to a noticeable decline in the volatility index.
C
Hold
8/24/2015Upgraded
Bioheart, Inc. (BHRT) was upgraded to C+ from C on 8/24/2015 due to a substantial increase in the valuation index and growth index. Total revenue increased 15.46% from $489.6 to $565.3.
Bioheart, Inc. (BHRT) was upgraded to C+ from C on 8/24/2015 due to a substantial increase in the valuation index and growth index. Total revenue increased 15.46% from $489.6 to $565.3.
C
Hold
7/1/2015Downgrade
Bioheart, Inc. (BHRT) was downgraded to C from C+ on 7/1/2015 due to a substantial decline in the valuation index.
Bioheart, Inc. (BHRT) was downgraded to C from C+ on 7/1/2015 due to a substantial decline in the valuation index.
C
Hold
6/16/2015Upgraded
Bioheart, Inc. (BHRT) was upgraded to C+ from C on 6/16/2015 due to a significant increase in the growth index and valuation index. Earnings per share increased from -$0.0018 to -$0.002, and operating cash flow increased 6.31% from -$361.5 to -$384.3.
Bioheart, Inc. (BHRT) was upgraded to C+ from C on 6/16/2015 due to a significant increase in the growth index and valuation index. Earnings per share increased from -$0.0018 to -$0.002, and operating cash flow increased 6.31% from -$361.5 to -$384.3.
C
Hold
3/11/2014Upgraded
Bioheart, Inc. (BHRT) was upgraded to C from C- on 3/11/2014 due to a substantial increase in the volatility index, total return index and growth index.
Bioheart, Inc. (BHRT) was upgraded to C from C- on 3/11/2014 due to a substantial increase in the volatility index, total return index and growth index.
OTC PK
03/14/2025 10:46AM Eastern
Quotes delayed
